Company news
HCW Biologics Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
November 17, 2024
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
November 13, 2024
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
August 22, 2024
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
March 31, 2024
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
November 13, 2023
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
November 7, 2023
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
September 5, 2023
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 10, 2023
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
June 13, 2023
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
May 8, 2023
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
April 26, 2023
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
April 12, 2023
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
April 2, 2023
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 27, 2023
HCW Biologics Enters CRADA with National Cancer Institute
December 7, 2022
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
December 6, 2022
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
November 7, 2022
HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights
November 6, 2022
HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights
August 11, 2022
U.S. Patent Issued to HCW Biologics for Foundational Platform Technology
August 2, 2022
HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022
May 22, 2022
HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 12, 2022
HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists
May 4, 2022
HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022
April 18, 2022
HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021
March 27, 2022
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest
March 23, 2022
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein
January 23, 2022
HCW Biologics Inc. Announces its Lead Product Candidate Shown to Augment Anti-Tumor Activity and Reduce Side Effects of Chemotherapy Regimens
January 19, 2022
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022
January 18, 2022
HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022
January 5, 2022
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year
December 12, 2021
HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights
November 11, 2021
HCW Biologics Receives FDA Clearance to Proceed with Phase 1b Clinical Trial for Immunotherapeutic HCW9218 for Pancreatic Cancer
October 27, 2021
HCW Biologics Announces Appointment of Two New Members to Board of Directors
October 26, 2021
HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic
August 23, 2021
HCW Biologics’ Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform
August 16, 2021
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights
August 12, 2021
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
July 21, 2021
HCW Biologics Inc. Announces Pricing of $56.0 Million Initial Public Offering
July 18, 2021
Decks
- Investor Presentation (March 2026)
Investor deck · 20 slides · March 2026
- IPO Roadshow (July 2021)
IPO roadshow · 12 slides · Jul 12, 2021